Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Caspase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28 result(s) found for: Caspase. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2010-022410-11 Sponsor Protocol Number: 33606.068.10 Start Date*: 2011-07-18
    Sponsor Name:MUMC
    Full Title: Topical Diclofenac and Vitamin D3 to treat Basal Cell Carcinoma
    Medical condition: Basal Cell Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004226-82 Sponsor Protocol Number: 10077 Start Date*: 2006-09-07
    Sponsor Name:University Hospitals of Leicester NHS Trust
    Full Title: PHARMACODYNAMIC STUDY OF ORAL MIRTOSELECT IN PATIENTS WITH SUSPECTED COLORECTAL DISEASE
    Medical condition: Patients with operable colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061451 Colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003752-79 Sponsor Protocol Number: PIONEER Start Date*: 2017-05-24
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: Randomised Phase II clinical trial PIONEER- A Pre-operative wIndOw study of letrozole plus PR agonist (Megestrol Acetate) versus letrozole aloNE in post-menopausal patients with ER-positive breast ...
    Medical condition: ER-positive, HER2-negative, invasive primary breast cancer of at least 1 cm size
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-006295-17 Sponsor Protocol Number: MedTrace-002 Start Date*: 2022-04-08
    Sponsor Name:MedTrace Pharma
    Full Title: A Phase 3, Multicenter, Open Label Study to Confirm the Diagnostic Potential of Intravenously Administered 15O- H2O to Identify Coronary Artery Disease During Pharmacological Stress and Resting Con...
    Medical condition: Coronary Artery Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10006896 CAD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-001601-16 Sponsor Protocol Number: GS-US-227-0102 Start Date*: 2007-04-13
    Sponsor Name:Gilead Sciences Incorporated
    Full Title: A Phase IIa, Double-blind, Randomised, Placebo-Controlled Dose Escalation Study to Evalulate the Safety, Tolerability, Pharmacokinetics and Activity of GS-9450, a Caspase Inhibitor, in Subjects wit...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-002053-24 Sponsor Protocol Number: 07_DOG03_133 Start Date*: 2007-10-26
    Sponsor Name:The Christie NHS Foundation Trust
    Full Title: A phase II study evaluating the use of concurrent cetuximab, irinotecan, oxaliplatin and UFT in the first line treatment of patients with metastatic colorectal cancer
    Medical condition: Advanced, inoperable or metastatic colorectal cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004473-32 Sponsor Protocol Number: IDN-6556-14 Start Date*: 2016-12-27
    Sponsor Name:Conatus Pharmaceuticals Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hyperten...
    Medical condition: Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10036200 Portal hypertension PT
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004336-35 Sponsor Protocol Number: IDN-6556-12 Start Date*: 2016-05-20
    Sponsor Name:Conatus Pharmaceuticals Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan (IDN-6556), an Oral Caspase Inhibitor, in Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004245-42 Sponsor Protocol Number: 10078 Start Date*: 2006-09-07
    Sponsor Name:University Hospitals of Leicester NHS Trust
    Full Title: PHARMACODYNAMIC STUDY OF ORAL MIRTOSELECT IN PATIENTS WITH SUSPECTED HEPATIC DISEASE
    Medical condition: Patients with operable liver metastases
    Disease: Version SOC Term Classification Code Term Level
    8.1 10024700 Liver metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004305-24 Sponsor Protocol Number: BCCItraconazole Start Date*: 2012-04-18
    Sponsor Name:Med Uni Graz, Univ. Klinik Dermatologie,Abteilung für Allgemeine Dermatologie
    Full Title: Inhibition of the Hedgehog Pathway in Basal Cell Carcinomas of Patients treated with Itraconazole for Onychomycosis
    Medical condition: Basal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    14.1 10042613 - Surgical and medical procedures 10004148 Basal cell carcinoma excision LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000543-13 Sponsor Protocol Number: UoL001204 Start Date*: 2016-12-28
    Sponsor Name:University of Liverpool
    Full Title: A window of opportunity study to assess the biological effects of enobosarm in oestrogen receptor positive, androgen receptor positive early breast cancer
    Medical condition: oestrogen receptor, androgen receptor positive early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    Population Age: Under 18, Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-001521-41 Sponsor Protocol Number: UoL001304 Start Date*: 2017-09-18
    Sponsor Name:University of Liverpool
    Full Title: A window of opportunity study to assess the biological effects of progesterone in premenopausal ER-positive, PgR-positive early breast cancer
    Medical condition: Premenopausal ER-positive, PgR-positive early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2013-004055-20 Sponsor Protocol Number: ICR-CTSU/2013/10040 Start Date*: 2014-09-23
    Sponsor Name:The Royal Marsden NHS Foundation Trust [...]
    1. The Royal Marsden NHS Foundation Trust
    2. The Institute of Cancer Research
    Full Title: A phase II randomised trial of biomarkers to assess (dose-) response in patients with metastatic castration resistant prostate cancer treated with radium-223.
    Medical condition: Castrate resistant prostate cancer with bone metastases.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005993 Bone metastases LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2019-004074-25 Sponsor Protocol Number: ABc2 Start Date*: 2020-08-12
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: A Phase II Open-Label Randomized COntrolled Pre-Surgical Feasibility Study of Antibiotic COmbinations in Early Breast Cancer
    Medical condition: We investigated, in a population of patients with breast cancer, the combined effect of azithrocyn, docyciclin and vitamin C on biomarkers associated with cell proliferation
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004865 10079328 Breast tumor excision LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000677-23 Sponsor Protocol Number: CLCL161A2201 Start Date*: 2012-10-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase II, multi-center, open-label, neoadjuvant, randomized study of weekly paclitaxel with or without LCL161 in patients with triple negative breast cancer
    Medical condition: Triple negative breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) ES (Completed) IE (Completed) IT (Completed) BE (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004909-33 Sponsor Protocol Number: LCTU122 Start Date*: 2015-09-21
    Sponsor Name:Manchester University NHS Foundation Trust
    Full Title: Thrombin Inhibition Preoperatively in Early Breast Cancer
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-002678-11 Sponsor Protocol Number: ICO-13-001 Start Date*: 2018-06-07
    Sponsor Name:Institut Català d’Oncologia
    Full Title: An open label biomarker pilot study of the antitumoral acrivity of denosumab in the pre-operative setting of early breast cancer
    Medical condition: early breast cancer
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2009-010572-20 Sponsor Protocol Number: CA198-002 Start Date*: 2009-10-12
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects with Advanced and/or Metastatic Solid Tumors
    Medical condition: Advanced and/or metastatic solid tumors
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-000499-83 Sponsor Protocol Number: 1386.4 Start Date*: 2017-05-04
    Sponsor Name:Boehringer Ingelheim bv
    Full Title: A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate safety, tolerability, pharmacodynamics, and harmacokinetics of different doses of orall...
    Medical condition: Non-alcoholic steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10076331 Steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) DE (Completed) IE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-000878-11 Sponsor Protocol Number: OMO1.01.02 Start Date*: 2017-06-08
    Sponsor Name:OCTIMET Oncology NV
    Full Title: A modular, multi-arm, multi-part, first time in patient study to evaluate the safety and tolerability of OMO-1, alone and in combination with anti-cancer treatments, in patients with locally advanc...
    Medical condition: Locally advanced, unresectable or metastatic solid malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) NL (Prematurely Ended) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 21:08:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA